There is much interest in the potential use of cyclooxygenase-2 (COX-2) selective inhibitors in combination with other cancer therapeutics. COX-2 is a key-role enzyme in prostaglandin synthesis and has been implicated in the pathogenesis of numerous canine and feline malignancies. There is little data on the potential role of COX-2 in canine lymphoma pathogenesis. To investigate the presence of COX-2 over-expression in canine normal, hyperplastic and neoplastic lymphatic tissues, 80 canine lymph node tissue samples (12 from non-pathologically enlarged normal lymph nodes, 24 from lymph node hyperplasias and 44 from lymphomas, 22 B-cell and 22 T-cell lymphomas) have been evaluated by immunohistochemistry to determine the enzyme expression. Scoring was performed according to previous studies and tissues scoring +2 and +3 were recorded as overexpressing. In hyperplastic lymph node tissues only a few macrophages were COX-2 positive, while six out of the 44 examined lymphomas (13.6%; 3 B- and 3 T-cell lymphomas) were COX-2 overexpressing. This is the first study describing COX-2 immunoreactivity neoplastic lymph nodes tissues. Even if a wider number of samples needs to be investigated to draw some firmer conclusions, these data suggest a rationale for further investigate COX-2 expression in these neoplasms for prognostic, chemopreventive and chemotherapic implications.

Immunohistochemical expression of COX-2 in normal. hyperplastic and neoplastic canine lymphoid tissues

ASPRONI, PIETRO;MILLANTA, FRANCESCA;POLI, ALESSANDRO
2014-01-01

Abstract

There is much interest in the potential use of cyclooxygenase-2 (COX-2) selective inhibitors in combination with other cancer therapeutics. COX-2 is a key-role enzyme in prostaglandin synthesis and has been implicated in the pathogenesis of numerous canine and feline malignancies. There is little data on the potential role of COX-2 in canine lymphoma pathogenesis. To investigate the presence of COX-2 over-expression in canine normal, hyperplastic and neoplastic lymphatic tissues, 80 canine lymph node tissue samples (12 from non-pathologically enlarged normal lymph nodes, 24 from lymph node hyperplasias and 44 from lymphomas, 22 B-cell and 22 T-cell lymphomas) have been evaluated by immunohistochemistry to determine the enzyme expression. Scoring was performed according to previous studies and tissues scoring +2 and +3 were recorded as overexpressing. In hyperplastic lymph node tissues only a few macrophages were COX-2 positive, while six out of the 44 examined lymphomas (13.6%; 3 B- and 3 T-cell lymphomas) were COX-2 overexpressing. This is the first study describing COX-2 immunoreactivity neoplastic lymph nodes tissues. Even if a wider number of samples needs to be investigated to draw some firmer conclusions, these data suggest a rationale for further investigate COX-2 expression in these neoplasms for prognostic, chemopreventive and chemotherapic implications.
2014
Asproni, Pietro; Vignoli, Massimo; Cancedda, S; Millanta, Francesca; Terragni, R; Poli, Alessandro
File in questo prodotto:
File Dimensione Formato  
Asproni et al_COX-2 in lymphoid tissues_J Comp Pathol 2014 - 151, 35.pdf

solo utenti autorizzati

Tipologia: Versione finale editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 875.71 kB
Formato Adobe PDF
875.71 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/383867
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 6
social impact